Pfizer has temporarily suspended the supply of its Premarin vaginal cream in India, citing supply chain challenges. As this product holds a significant share of the local conjugated estrogen market, the move creates a potential treatment gap for patients. Investors may monitor how long this disruption lasts and if it impacts the company’s local revenue segment.
Pfizer has confirmed a temporary halt in the supply of its Premarin vaginal cream within the Indian market. The company attributed this decision to specific supply chain challenges but has indicated it is working to resolve these issues and restore product availability. This development is notable because Premarin is a leading treatment option for genitourinary syndrome of menopause in India, a condition that currently faces limited therapeutic alternatives in the region.
Market Position and Sales Impact
The product has seen significant growth in recent years. Industry data for the year ending June 2026 shows that Premarin reached sales of approximately 266 million rupees. This figure highlights a substantial jump from the 62 million rupees recorded in 2022. By volume, the product accounted for more than 620,000 units sold in the 12 months leading up to June 2026, which represents over half of the market share for conjugated estrogen treatments in India. Consequently, the temporary exit of such a high-volume product may impact the company's specific segment revenue in the coming quarters.
Treatment Alternatives and Sector Context
The Indian pharmaceutical landscape for menopause care has historically been concentrated among a few key players. Following the supply disruption, patients and healthcare providers are left with fewer choices, as alternatives like Torrent Pharmaceuticals' Evalon are among the limited options available for similar symptoms. Reports indicate that the product has been difficult to source through major digital pharmacy platforms like Tata 1MG and Netmeds since late 2025. This scarcity highlights the challenges in the domestic market, where access to specialized hormonal treatments remains constrained compared to global markets.
Investor Monitorables
For investors, the primary concern remains the duration of this supply chain disruption. While India represents a smaller fraction—approximately 2.8% as of 2025—of the global estrogen replacement therapy market, the rapid growth in value and unit volume suggests that it is an important niche segment for the company. The next key updates to track include official timelines from the company regarding the resumption of imports or local availability, and whether this supply pressure affects the firm’s competitive standing against peers like Torrent Pharmaceuticals. If the supply constraint persists, there is a risk that patients may shift to alternative therapies, potentially leading to a permanent change in market share dynamics.